Objectives: The feasibility and long-term outcomes of mitral valve (MV) repair in patients with infective endocarditis (IE) remain unclear.
Central Message
Mitral repair for infective endocarditis has better perioperative and late outcomes than mitral replacement, and is recommended whenever possible, even for patients with an active infection status.
Perspective
The feasibility and long-term outcomes of mitral repair for infective endocarditis remain unclear. This nationwide population-based propensity score-matching study showed better perioperative and late outcomes after mitral repair than valve replacement, even in patients with active endocarditis. In low-volume centers, the repair rate was significantly lower and the beneficial effect of repair was less apparent.
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The incidence of infective endocarditis (IE)-related hospitalization in Taiwan is approximately 6.43 episodes per 100,000 people annually. 1 Despite improvements in diagnosis and management, in-hospital mortality of IE remains between 20% and 30%. 2, 3 Although many patients are treated successfully with antibiotics, numerous patients still require surgery because of persistent sepsis, severe valvular destruction with heart failure, or repeated embolic complications.
If mitral valve (MV) surgery is indicated, valve repair is recommended over valve replacement whenever possible. 4 The feasibility and durability of repair in degenerative mitral regurgitation caused by leaflet prolapse or chordal rupture have been well established, [5] [6] [7] [8] but the reparability and long-term outcomes of repair in IE remain questionable. Several studies have reported improved outcome after MV repair compared with MV replacement, [8] [9] [10] [11] but others have not reported significant differences. 12, 13 However, these were all retrospective studies with an inherent selection bias. Furthermore, long-term follow-up was limited. Therefore, we conducted this study to evaluate the perioperative and late outcomes of MV repair and replacement in patients with IE by using a nationwide population-based cohort study design with propensity score matched analysis to minimize confounding factors.
METHODS

Data Source
Taiwan's National Health Insurance (NHI) program is a universal compulsory health insurance system providing comprehensive medical care coverage to 99% of the country's 23.74 million people. Derived from the NHI program, the National Health Insurance Research Database (NHIRD) contains data that accurately represent Taiwan's population, with only minimal omitted data and a small participation bias.
The NHI program has a consistent data encryption process, allowing continuous tracking of all claims of each individual within the program. Moreover, because of the mandatory enrollment and affordability of the NHI program, even people who emigrate to other countries retain their NHI identities and return to Taiwan for medical treatment, especially those who have undergone major surgeries. Thus, nearly complete long-term follow-up of all patients is possible.
All data in the NHIRD are deidentified and anonymized to protect privacy; thus, this study was exempt from a full review by the Ethics Institutional Review Board of Chang Gung Memorial Hospital. Other relevant details have been described in previous publications.
14-16
Study Population
A total of 15,111 patients who received MV surgery between January 1, 2000 and December 31, 2013 were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes (35.12, 35.23, and 35.24) and Taiwan NHI procedure codes (68015, 68016, 68017, and 68018), which are used for reimbursement claims (Figure 1 ). Of these patients, 2025 (13.4%) had a history of IE or a principal diagnosis of IE during the index hospitalization. ICD-9-CM diagnosis codes (421.0, 421.1, and 421.9) were used to identify the diagnosis of IE. Patients were excluded if they were aged younger than 18 years or had received previous valve surgery.
During the study period, 1999 adult patients underwent first-time MV surgery because of IE. Types of MV surgery were distinguished using ICD-9-CM procedure codes (35.12 for MV repair; 35.23 and 35.24 for MV replacement). Patients were more likely to undergo valve replacement (1575 patients; 78.8%) than repair (424 patients; 21.2%) in our study population. Longitudinal data for MV repair and replacement revealed an increase in the proportion of valve repair from 2000 to 2013 (P for trend ¼ .047; Figure 1 , B). To minimize potential selection bias, we calculated a propensity score from selected variables (Table 1) and matched each patient in the MV repair group with each patient in the MV replacement group. Finally, 352 patients from each group were identified and were eligible for analysis (Figure 1, A) .
Baseline Characteristics and Outcomes
The examined demographic characteristics are listed in Table 1 . Active IE was defined as a new diagnosis of IE during the index hospitalization (Table E3) . Hospital level and the hospital's total volume of valve surgery and MV repair within the study period were also examined according to NHIRD claims data. Other surgical details were identified using Taiwan NHI procedure codes.
The examined outcomes during the index hospitalization are listed in Table 2 . The primary outcome during follow-up was a composite of all-cause mortality, redo MV surgery, any stroke, major bleeding, and readmission for heart failure.
Death records and records of withdrawal from the NHI program were used to identify mortality. This method has been validated in previous studies. 17, 18 The date on which a patient was admitted for MV surgery was defined as the index hospitalization. The patients were followed from their index hospitalization to December 31, 2013 or date of death, with a >99% completeness of follow-up.
Statistical Analysis
Before comparing outcomes between the MV repair and MV replacement groups, we performed propensity score matching to minimize the selection bias caused by an imbalanced distribution of baseline characteristics. The propensity score was calculated on the basis of clinical and surgical characteristics (Table 1 lists all variables, except for follow-up years), including date of the index hospitalization, which might be related to the probability of receiving MV repair. Although the number of patients was considerably greater in the MV replacement group, we adopted a 1:1 matching ratio to ensure higher precision and lower bias of treatment effects. 19 Greedy nearest neighbor matching was performed in which the caliper width was set as 0.2 of the SD of the logit of the propensity score. 20 An absolute standardized mean difference (ASMD) of <0.1 after propensity score matching was considered to indicate an adequate balance of the distribution of covariates. 21 Data regarding clinical and surgical characteristics are presented as frequency and proportion for categorical variables or as mean AE SD for continuous variables. We compared the perioperative and in-hospital outcomes between the MV repair and MV replacement groups using a McNemar test for categorical parameters (eg, in-hospital mortality) or a paired sample t test for continuous parameters (eg, volume of transfusion). The risks of outcomes related to death (ie, all-cause mortality and composite end point) were compared between the study groups using a Cox proportional hazards model. In addition, we compared the risks of other late outcomes (eg, redo MV surgery, any stroke, major bleeding, and readmission for heart failure) between the study groups using a subdistribution hazards model, in which death was considered a competing risk. 22 The Cox model as well as the subdistribution hazards model were stratified according to the matched pairs. For time to event outcomes, we performed a sensitivity analysis using doubly robust adjustment. 23 The survival curves were plotted using Kaplan-Meier estimates along with a log rank test to compare group differences before propensity score matching. Finally, the proportion of microbiology between the study groups was compared using a McNemar test. Data analysis and propensity score matching were conducted using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
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RESULTS
Patient Characteristics
Before propensity score matching, patients in the MV repair group were younger, had a lower prevalence of active IE, had a lower proportion of urgent or emergent surgery, and had a lower prevalence of comorbidities including diabetes mellitus, coronary arterial disease, and end-stage renal disease (ASMD > 0.1). Considering hospital level and experience, medical centers and hospitals with higher volumes of valve surgery or MV repair were more likely to perform MV repair, whereas regional and district hospitals as well as those with less experience had higher proportions of MV replacement. After propensity score matching, all baseline characteristics and concomitant procedures were similar between the MV repair and replacement groups (ASMD<0.1). Differences in hospital level and volumes were also minimized (Table 1) . Table 2 shows the in-hospital outcomes of MV repair versus MV replacement. In the propensity score-matched samples, the risks of new-onset stroke (6.5% vs 11.4%; P ¼ .036), new-onset ischemic stroke (3.7% vs 8.5%; P ¼ .014), massive blood transfusion (11.4% vs 20.2%; P ¼ .002), and in-hospital mortality (6.3% vs 10.8%; P ¼ .037) were significantly lower in patients who received MV repair than in those who received MV replacement. Compared with those who received MV replacement, patients who received MV repair had shorter intensive care unit duration of stay, shorter hospital stays, and lower in-hospital expenditures.
In-Hospital Outcomes
Late Outcomes
During a mean follow-up of 4.8 years (SD, 4 years), the rates of the composite end point were 29.3% and 41.2% in the MV repair and MV replacement groups, respectively (Table E2 ). This result indicates a beneficial effect in the MV repair group versus the MV replacement group (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.46-0.850.8; P ¼ .003). The proportions of mortality were 19.3% and 31% in the MV repair and MV replacement groups, respectively. A similar result was observed when comparing group differences, with patients in the MV repair group having a significantly lower late mortality risk than those in the MV replacement group (HR, 0.52; 95% CI, 0.37-0.75; P < .001). However, no statistical difference existed regarding MV reoperation, stroke, major bleeding, or readmissions caused by heart failure ( Figure 2 , A, Table E1 ). Figure 2 , B illustrates the Kaplan-Meier event-free survival (free from composite end point) curves derived for the 2 groups.
Subgroup Analysis
To evaluate which patients would benefit from MV repair the most (or least), we divided them into subgroups according to the following characteristics: age, gender, whether valve surgery was performed during active IE, urgent or emergent surgery, previous stroke, gastrointestinal bleeding, rheumatic heart disease, concomitant procedure, concomitant valve surgery, concomitant aortic valve replacement with mechanical prosthesis, and hospital volume of valve surgery and MV repair surgery (Figure 3) . The beneficial effects of MV repair on the composite end point during follow-up were comparable across various levels of the selected patient characteristics (P for interaction, >.05). A trend was noted in which the beneficial effect of MV repair was less apparent in patients who received surgery in hospitals with a lower volume of MV repair; however, this was nonsignificant (P for interaction, .091).
Patients Who Underwent Valve Surgery During Active IE and Their Microbiology
We analyzed patients who underwent valve surgery during active IE before propensity score matching (Table E3 ). The results revealed that patients who underwent MV repair had lower all-cause mortality during follow-up (P for log-rank test, <.001; Figure 4) . When comparing microbiology, we discovered that patients with active staphylococcal infections seemed to have a lower opportunity for MV repair, whereas patients with streptococcal infections had contrary results ( Figure E1 ). However, the differences were not statistically significant.
DISCUSSION
Since the first series in 1990, 24 cardiac surgeons worldwide have been attempting to answer the question of whether valve repair or replacement is better for patients with MV-IE; nevertheless, no solid conclusions have been reached. In retrospective studies that compared MV repair and replacement in patients with IE, patients in replacement groups were usually older, had more comorbidities, and were more critically ill preoperatively because of congestive heart failure or uncontrolled sepsis. 9, 10, 13 Hence, the outcomes were influenced not only by surgical procedures, but also by baseline conditions. However, conducting a randomized control trial is nearly impractical because of variable degrees of valve destruction, varying clinical conditions, and ethical concerns. To the best of our knowledge, this study is the first to compare MV repair and replacement for patients with IE using propensity score matching. With this method, we minimized differences in baseline patient conditions and hospital factors. Despite similar baseline characteristics, perioperative and late outcomes were significantly improved after MV repair than replacement in our study.
Repair Versus Replacement
The beneficial effect of MV repair can be attributed to 2 reasons. First, when the integrity of the mitral apparatus is preserved, left ventricular function is preserved more effectively. 25 Second, MV repair avoids the inherent risks of prosthetic heart valves. If a mechanical valve is implanted, thromboembolism or anticoagulant-induced hemorrhage might occur. If a bioprosthetic valve is used, structural deterioration is inevitable. Several studies have shown better short-and long-term outcomes after MV repair than replacement, even in elderly patients. 6, 7, 26, 27 Although not statistically significant, we showed the trend that MV repair is related to a reduction in readmission for heart failure, stroke, major bleeding, and redo MV surgery during follow-up. As an accumulation of all of the aforementioned events, the composite end point and all-cause mortality during follow-up were significantly lower in the MV repair group than in the MV replacement group. This finding indicates that MV repair provides greater improvements to late outcomes than MV replacement for IE patients.
Subgroup Analysis
Through subgroup analysis, we discovered that the beneficial effect of MV repair on the composite end point during follow-up was significant regardless of patient age, gender, or active or treated IE status. On the contrary, we found that patients who received surgery in hospitals with the highest valve surgery volumes benefited from MV repair significantly, whereas those who received surgery in the lowest volume hospitals did not. Moreover, in hospitals within the lowest MV repair volume quartile, patients who underwent MV replacement seemed to have lower numerical risk of the composite end point.
Published articles have indicated higher MV repair rates and lower mortality in high-volume centers than in low-volume centers. 28 In our study, the repair rates in centers with high MV repair volumes were significantly higher than those in centers with low volumes (54.0% vs 4.0%; P <.01). Furthermore, the outcomes of MV repair performed in low-volume hospitals did not outperform those of MV replacement. This finding supports our belief that for patients with IE, an experienced team specialized in MV repair surgery is crucial to a successful repair. 
MV Repair in the Real World
Despite the well known benefits of MV repair over replacement and guideline suggestions, 29 the proportion of MV repair in patients with IE remains low. Gammie et al reported a 29.7% frequency of MV repair for patients with IE between 1994 and 2003 in the United States. 8 During the same period, the MV repair rate was 45.7% in non-IE cases. Moreover, in the last year of their study period, the frequency rates of mitral repair for IE and non-IE patients were 34.5% and 59.8%, respectively. In our study, the overall frequency of MV repair for IE in Taiwan during the 13-year period was 21.2%, and the frequency of MV repair in lowest-volume quartile hospitals was<10%. Although the proportion of MV repair has been increasing, it never exceeded 30% in our study period.
Unlike degenerative MV disease, endocarditis can cause severe destruction of leaflet and paravalvular structures, thus increasing the complexity and difficulty of valve repair. The frailty of the valve in patients with IE also raises concerns about the long-term durability of the repair. However, some authors have reported an MV repair rate of 75% to 82.7% in patients with IE with preferable results. 12, [30] [31] [32] Because the benefit of MV repair in IE has been shown, a repair-first strategy for MV surgery must be incorporated for patients with IE; early referral to centers specialized in valve surgery can maximize the probability of successful repair and optimize patient outcome.
Study Limitations
This study has some limitations because of the administrative nature of the NHIRD. First, the diagnosis of IE was strictly on the basis of the ICD-9-CM system. Coding errors or misclassifications were possible. However, other studies have indicated that these codes are reliable substitutes for chart-based IE diagnosis on the basis of the revised Duke criteria. 33, 34 Validation analysis also revealed good agreement between the coded IE diagnosis in Taiwan's NHIRD and that of clinically definite or possible IE in a tertiary center in Taiwan. 35 Furthermore, the type of MV surgery was doubly confirmed according to ICD-9-CM and NHI procedure codes. Therefore, we believe our study design to be reliable and the effects of code errors on our conclusions to be limited.
Second, several detailed clinical and surgical data are not available in the NHIRD, including lab data, ventricular ejection fraction, mitral regurgitation severity, heart failure symptoms, surgical indication and timing, antibiotics course, infection control status, MV repair techniques, and prosthetic valve brand and size, which might have influenced patient outcomes and our analysis. However, the NHI program has strict regulations regarding surgery, examination, and medication reimbursements. Comprehensive reviews of all medical records including imaging studies and lab data ensure that specific exams or interventions are granted only to patients who are indicated. Thus, national regulation by universal indication of treatment protocols could limit the potential bias of unavailable data.
Third, our study is observational in nature and the evidence level was limited by the database post hoc analysis. Despite adjustments for known confounders by using propensity score matching, unaddressed residual biases remain, including the aforementioned hemodynamics status, echocardiographic parameters, and extent of MV involvement. MV replacement might be more likely to be performed in cases in which the valve is more severely affected and the larger extent of the disease rather than the procedure itself can explain worse outcomes. Therefore, we could only investigate associations but could not infer causation.
CONCLUSIONS
According to this nationwide population-based propensity score-matching study, MV repair for patients with IE has better perioperative and late outcomes compared with MV replacement. However, the beneficial effects of MV repair are uncertain in hospitals with lower MV repair volumes. Therefore, MV repair performed by an experienced team specialized in valve surgery rather than MV replacement is recommended for IE patients whenever possible, even with an active infection status (Video 1).
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